-
Mashup Score: 9An Overview of the Medicare Part D Prescription Drug Benefit | KFF - 5 month(s) ago
This fact sheet includes the latest information and data about the Medicare Part D prescription drug benefit, including current plan information, the standard benefit parameters, low-income assistance, the latest available enrollment data, and Part D program spending and financing. It also highlights upcoming changes to Part D under the Inflation Reduction Act.
Source: www.kff.orgCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 9An Overview of the Medicare Part D Prescription Drug Benefit | KFF - 5 month(s) ago
This fact sheet includes the latest information and data about the Medicare Part D prescription drug benefit, including current plan information, the standard benefit parameters, low-income assistance, the latest available enrollment data, and Part D program spending and financing. It also highlights upcoming changes to Part D under the Inflation Reduction Act.
Source: www.kff.orgCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 0
This cross-sectional study evaluates the cost savings of state-led manufacturing and selling of biosimilar insulin.
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance - 10 month(s) ago
This cohort study investigates out-of-pocket spending for ultra-expensive drugs in the Medicare Part D program vs commercial insurance from 2013 through 2019.
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0Generic Prescribing Patterns Among 340B-Eligible and Non-340B Prescribers in Medicare Part D - 10 month(s) ago
This cross-sectional study examines generic prescribing patterns for 2020 among 340B-eligible and non-340B clinicians in the Medicare Part D program to assess whether 340B revenue incentives may influence prescribing.
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1
This cross-sectional study evaluates the cost savings of state-led manufacturing and selling of biosimilar insulin.
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 2Growing Financial Burden From High-Cost Targeted Oral Anticancer Medicines Among Medicare Beneficiaries With Cancer - 2 year(s) ago
PURPOSE: The rapidly rising costs of targeted oral anticancer medicines (TOAMs) raise concerns over their affordability. Our goal was to examine recent trends in the uptake of TOAMs among cancer patients with Medicare Part D, the share of TOAM users who reached catastrophic coverage, and the annual spending on TOAMs in the catastrophic phase. METHODS: Using the 5% SEER-Medicare, we included…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Key Facts About Medicare Part D Enrollment and Costs in 2022 - 2 year(s) ago
This analysis provides the latest data about Medicare Part D enrollment, premiums, and cost sharing in 2022 and trends over time, including information about stand-alone prescription drug plans (PD…
Source: KFFCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 7Key Facts About Medicare Part D Enrollment and Costs in 2022 - 2 year(s) ago
This analysis provides the latest data about Medicare Part D enrollment, premiums, and cost sharing in 2022 and trends over time, including information about stand-alone prescription drug plans (PD…
Source: KFFCategories: Latest Headlines, PulmonologyTweet-
Medicare enrollees this year pay an average $40 per month for stand-alone #PartD drug coverage, much more than the $11 per month average for #MedicareAdvantage drug coverage. Those in stand-alone plans also face much higher annual deductibles on average: https://t.co/fqBE8MxOBL https://t.co/hhnT6bs3IM
-
-
Mashup Score: 5Key Facts About Medicare Part D Enrollment and Costs in 2022 - 2 year(s) ago
This analysis provides the latest data about Medicare Part D enrollment, premiums, and cost sharing in 2022 and trends over time, including information about stand-alone prescription drug plans (PD…
Source: KFFCategories: Latest Headlines, PulmonologyTweet
NEW: In 2024, 709 stand-alone Medicare prescription drug plans will be offered across 34 regions nationwide, an 11% decrease from 2023 and the lowest number available since Part D’s inception in 2006. Our fact sheet provides an overview of #PartD: https://t.co/dHnH58xtly https://t.co/KXMjzDTgjo